Haixiang Pharmaceutical (002099): Exchange rate fluctuations affect apparent performance, CDMO orders are growing rapidly
Haixiang Pharmaceutical (002099): The pharmaceutical sector continues to grow and wait for the inflection point of fundamentals
Deepin* Company* Haixiang Pharmaceutical (002099): Special API supplier Peinan products, global leader of clindamycin, in-depth cooperation between MNC to expand C (D) MO capabilities
Haixiang Pharmaceutical (002099): Pharmaceutical business continues to gain strength, waiting for dye inflection point
Haixiang Pharmaceutical (002099) 2022 China News comment report: the net interest rate of the rapid growth of pharmaceutical business increases
Haixiang Pharmaceutical (002099): Haixiang Pharmaceutical depth report: the pharmaceutical sector has entered a new growth cycle
Haixiang Pharmaceutical Industry (002099): an undervalued leader of domestic pharmaceutical raw materials
Haixiang Pharmaceutical (002099) 3 Quarterly report in 2019 comments: KN-R prices enter the bottom area of steady growth of pharmaceutical business
Haixiang Pharmaceutical (002099): the dye plate is declining and the pharmaceutical sector is still growing at a high speed.
Haixiang Pharmaceutical (002099): the performance of the pharmaceutical sector is beautiful and the integration of dyestuff is expected in the future.
Haixiang Pharmaceutical (002099) 2019 China report comments: API exceeding expectations dyestuff is expected to usher in demand reversal focus on new capacity launch in the fourth quarter
Haixiang Pharmaceutical (002099): 19Q1's excellent performance is expected to continue to grow in the future.
Comments on Haixiang Pharmaceutical (002099) Quarterly report in 2019: the rise in volume and price of dye medicine with two-wheel drive led to a big increase in the company's performance.
Haixiang Pharmaceutical (002099) Quarterly report and first half performance Forecast comments: pharmaceutical, dye two-wheel drive performance is in line with expectations
Haixiang Pharmaceutical Industry (002099) investigation report: the dual main industries of dye and medicine develop integrated production and lay the foundation for growth.
Haixiang Pharmaceutical Industry (002099): the advantage of integration shows great potential for growth.
海翔药业(002099):染料小品种龙头 未来将长期受益于一体化生产
海翔药业(002099)事件点评:活性染料KN-R有望提价 全产业链龙头业绩弹性大
海翔药业(002099)中报点评:环保限产背景下活性染料价格维持高位 行业龙头盈利能力持续提升
海翔药业(002099)半年业绩快报点评:KN-R活性艳染料价格上涨 行业龙头中报业绩稳步上升
No Data
No Data